Skip to content
lifestyle.briefmobile.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Outlook Therapeutics, Inc.
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
May 6, 2026
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
May 4, 2026
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
May 4, 2026
Outlook Therapeutics Announces Proposed Public Offering
May 4, 2026
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
May 3, 2026
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
May 1, 2026
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
April 29, 2026
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
April 28, 2026
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
March 10, 2026
←
Previous Page
1
2